Investing.com - Zynerba Pharma (NASDAQ: ZYNE) reported first quarter EPS of $-0.210, $0.04 worse than the analyst estimate of $-0.173. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Zynerba Pharma's stock price closed at $0.360. It is down -35.390% in the last 3 months and down -61.400% in the last 12 months.
Zynerba Pharma saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Zynerba Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Zynerba Pharma's Financial Health score is "weak performance".
Check out Zynerba Pharma's recent earnings performance, and Zynerba Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar